Label-free array systems market seen reaching $2.1 billion by 2030

The label-free array systems market is projected to grow from $1.48 billion in 2025 to $1.59 billion in 2026, with demand rising from pharmaceutical research, CRO adoption and chronic-disease monitoring needs. North America led in 2025, while Asia-Pacific is expected to post the fastest growth through 2030.

Why it matters: - Label-free array systems are becoming more important as drug developers, researchers and contract research organizations need faster, real-time ways to measure molecular interactions. - Rising chronic disease rates add to demand for diagnostic and monitoring tools that do not require chemical or fluorescent labels. - The market is also tied to wider adoption of high-throughput screening, kinetics analysis and affinity mapping.

What happened: - The label-free array systems market is projected to rise from $1.48 billion in 2025 to $1.59 billion in 2026. - The forecast implies 7.6% growth for 2026. - The market is expected to reach $2.1 billion by 2030. - The projected CAGR from 2026 to 2030 is 7.2%. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Label-free array systems detect molecular interactions without chemical or fluorescent labeling. - The systems measure changes in mass, refractive index or electrical impedance to identify biomolecules. - Growth in the market has been supported by biosensing advances, pharmaceutical research and development, academic and research institution expansion, and continued use of conventional biosensors. - The report points to surface plasmon resonance and bio-layer interferometry as key technologies supporting future growth. - Contract research organizations are expected to increase adoption of label-free array systems. - Demand is rising for high-throughput and automated platforms. - The market is also benefiting from interest in real-time molecular interaction analysis and expanded drug discovery and protein-protein interaction studies. - Integration with artificial intelligence and big data analytics is emerging as a major trend. - A free sample of the market report is available here. - The full report is available here.

Between the lines: - The market's growth story is less about one single technology shift and more about several overlapping forces: chronic disease prevalence, automation needs and better biosensing tools. - The report's emphasis on AI and big data suggests buyers are looking beyond standalone instruments and toward workflow integration. - The CDC data cited in the release underscores why demand for earlier and more precise detection tools may keep rising. - The report said that in 2023, 76.4% of US adults had one or more chronic conditions, equal to 194 million people. - The CDC data also showed 51.4% of US adults, or 130 million people, had multiple chronic conditions. - The release said prevalence rose with age, reaching 93.0% among older adults for one or more chronic conditions and 78.8% for multiple chronic conditions.

What's next: - The label-free array systems market is likely to keep expanding as more users adopt real-time, high-throughput biosensing platforms. - Asia-Pacific growth will be a key regional story to watch through 2030. - Future market gains will likely depend on continued advances in sensitivity, accuracy and automation. - Broader use in drug discovery and protein interaction research should support ongoing demand.

The bottom line: - Label-free array systems are moving from niche research tools toward broader use in drug development and diagnostics, with the market on track for steady growth through 2030.